Hymont 4 Chewable Tablet contains Montelukast 4 mg, a leukotriene receptor antagonist used primarily for the prophylaxis and chronic treatment of asthma and to relieve symptoms of seasonal allergic rhinitis. Montelukast works by selectively blocking leukotriene D4 at the cysteinyl leukotriene receptor in the lungs and bronchial tubes, thereby reducing inflammation, bronchoconstriction, mucus production, and airway edema. This medication is indicated for pediatric patients aged 2 to 14 years to prevent asthma exacerbations and improve pulmonary function, as well as to alleviate nasal congestion, sneezing, and rhinorrhea associated with allergic rhinitis. Hymont 4 Chewable Tablet is designed for ease of administration in children who may have difficulty swallowing conventional tablets. It is typically administered once daily in the evening, with or without food. Common adverse effects may include headache, abdominal pain, cough, and upper respiratory infections, although it is generally well tolerated. Montelukast should be used with caution in patients with a history of neuropsychiatric events. It is important to continue other asthma control medications unless otherwise directed by a healthcare professional. Hymont 4 Chewable Tablet offers an effective and convenient option for managing pediatric asthma and allergic rhinitis under medical supervision.